Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS

J. A. Cohen; Marco Rovaris; Andrew Goodman; David Ladkani; Daniel Wynn; Massimo Filippi

doi:10.1212/01.wnl.0000257109.61671.06

Abstract

1 min read

Glatiramer acetate (GA) 40 mg was safe and well tolerated. The overall efficacy results suggested that a 40-mg dose of GA may be more effective than the currently approved 20-mg daily dose in reducing MRI activity and clinical relapses.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2010

Phase III dose‐comparison study of glatiramer acetate for multiple sclerosis

Giancarlo Comi, Jeffrey A. Cohen, Douglas L. Arnold, Daniel Wynn, Massimo Filippi

Article2006

Results of a Randomized, Double-Blind, Parallel-Group Study Assessing Safety and Efficacy of 40 mg vs. 20 mg of Glatiramer Acetate on MRI-Measured Disease Activity in RRMS.

J. A. Cohen, Marco Rovaris, Andrew Goodman, Massimo Filippi

Article2002

Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses

Marco Rovaris, Maria Codella, Lucia Moiola, Angelo Ghezzi, Mauro Zaffaroni, Gianluigi Mancardi, Elisabetta Capello, Francesco Sardanelli, Giancarlo Comi, Massimo Filippi

Article2003

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials

Filippo Martinelli Boneschi, Marco Rovaris, Kenneth P. Johnson, Aaron Miller, Jerry S. Wolinsky, David Ladkani, Galia Shifroni, Gıancarlo Comı, Massimo Filippi

Article2007

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

Marco Rovaris, Giancarlo Comi, Maria A. Rocca, Paola Valsasina, David Ladkani, E Pieri, S. Weiss, Galia Shifroni, J. S. Wolinsky, Massimo Filippi, European Canadian Glatiramer Acetate Study Group